The causative mutation in the majority of cases of myotonic dystrophy has been shown to be the expansion of a CTG trinucleotide repeat, but the mechanism(s) by which this repeat leads to the very complex symptomatology in this disorder remains controversial. We have developed a highly sensitive and quantifiable assay, based on competitive RT-PCR, to test the hypothesis that the expansion disrupts the expression of the genes in its immediate vicinity, DMPK, 59 and DMAHP. In order to avoid cell culture-induced artifacts we performed these experiments using adult skeletal muscle biopsy samples and analysed total cytoplasmic poly(A) + mRNA levels for each gene simultaneously, as this is more physiologically relevant than allele-specific levels. There was considerable overlap between the expression levels of the three genes in myotonic dystrophy patient samples and samples from control individuals. However, in the myotonic dystrophy samples we detected a strong inverse correlation between the repeat size and the levels of expression of DMPK and 59. This is the first report of a possible effect of the CTG expansion on gene 59. Our results indicate that whilst a simple dosage model of gene expression in the presence of the mutation is unlikely to be sufficient in itself to explain the complex molecular pathology in this disease, the repeat expansion may be a significant modifier of the expression of these two genes.
INTRODUCTION
Myotonic dystrophy (DM) is the commonest form of adult onset muscular dystrophy with an average prevalence of 1/8000 in the Caucasian population. The disorder is characterized by anticipation and very variable symptom presentation. In the mildest cases, the patients may present with bilateral cataracts from their fourth decade onwards, whereas in the most severe cases infants are born with skeletal muscle hypotonia which can lead to neonatal respiratory insufficiency. However, skeletal muscle symptoms of weakness, wasting and myotonia are common in the majority of adult patients. The causative mutation in the great majority of DM cases is the expansion of a CTG trinucleotide repeat (1) (2) (3) (4) (5) (6) . In the unaffected population, the repeat ranges from five to 46 copies but in the DM patient population the repeat range is extensive. In minimally affected patients the repeat (sized from peripheral blood leukocyte DNA) ranges from 50 to 100 copies, whereas in the most severely congenitally affected patients the repeat may be several kilobases in size (7) . The expanded repeat is both mitotically and meiotically unstable and the size of the repeat correlates broadly, but not absolutely, with symptom severity.
The CTG repeat expansion which underlies DM is located in the 3'-untranslated region (3'-UTR) of a serine-threonine protein kinase gene, DMPK (3) . This gene is widely expressed, with particularly high expression levels in the heart, brain and skeletal muscles, but its intracellular targets remain unclear. DMPK lies in an extremely gene-rich area of chromosome 19. Gene 59 is located <1 kb upstream of the DMPK start site and encodes a putative WD repeat protein, most highly expressed in the brain and testis (8) . A further gene, DMAHP (DM locusassociated homeodomain protein) lies <1 kb downstream of the 3'-end of DMPK. This gene appears to have fairly widespread but low level expression and its targets are currently unidentified (9) .
The mechanism by which an untranslated repeat leads to the observed symptoms remains unclear. The expanded repeat has been shown to bind mRNA-binding proteins (10) (11) (12) , which leads in an in vitro assay to abnormal post-transcriptional processing of cardiac troponin T (13) . It has also been suggested that the expansion may lead to variations in the levels of the genes in its immediate vicinity. The majority of reports have suggested that there is a decrease in levels of the mature + To whom correspondence should be addressed. Tel: +44 181 846 7250; Fax: +44 181 846 7330; Email: n.carey@ic.ac.uk Downloaded from https://academic.oup.com/hmg/article-abstract/8/6/1053/600172 by guest on 11 April 2019 processed transcript from the DMPK allele which bears the expanded repeat (14) (15) (16) (17) (18) ; this is probably a consequence of nuclear sequestration of the expanded transcript (17, 18) . The data for DMAHP expression is more controversial. Two studies have reported a decrease in expression from the allele on the expansion chromosome, possibly related to the loss of a DNase I hypersensitive site (19, 20) . However, a third study failed to show any detectable difference in DMAHP expression between DM and control material. The same study also reported no change in 59 expression levels between patient and control material (17) .
An understanding of the molecular consequences of the DM CTG expansion is essential for developing a model of disease progression in these patients. This in turn will be the critical framework for the rational design of therapeutic strategies. Many of the reported studies of expression from the DM locus have suffered from two possible problems which have rendered their interpretation problematic, i.e. they have used cultured cells or cell lines rather than native tissues and their gene expression quantification techniques have been insufficiently sensitive and/or reproducible. In order to address this problem, we have developed DM locus gene expression assays based on competitive RT-PCR. Our data show that whilst overall expression of the DM locus genes in the skeletal muscle samples shows considerable overlap between the DM and non-DM populations, there is a significant inverse correlation between the size of the repeat and the expression levels of DMPK and 59.
RESULTS
All PCR conditions were initially determined using the control and competitor plasmids. These demonstrated that for each gene the normal and competitor fragments were detected with the same sensitivity and that the reaction was still linear at 30 cycles (data not shown). The competitive RT-PCRs were then performed for each cDNA sample. A typical graph, in this case for detection and calculation of DMPK content, is shown in Figure 1 . Figure 2 shows the amounts of the three DM locus genes, normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), for the skeletal muscle biopsies from the three groups (log scale y-axis for clarity). The number of samples within each patient group is variable between the genes where no acceptable straight-line relationship could be calculated for a sample or where the y = 0 point was off scale. In all cases there is a noticeably wide range of expression levels for the genes.
Relative expression profiles

Means and statistical analyses
The mean level of gene expression for each of the DM locus genes was calculated and the results are shown in Figure 3 . The standard deviations are in most cases extensive, as would be anticipated from the widespread expression shown in Figure 2 . For DMPK, expression levels were significantly lower in samples from DM patients than those from myopathic controls (P = 0.0256). However, examination of the data shows that there was also a small but statistically significant (P = 0.0489) increase in expression in samples from myopathic controls compared with samples from unaffected controls. The apparent decrease in DMPK mRNA levels in DM patient material compared with myopathic controls, therefore, actually represents increased levels of DMPK expression in our myopathic controls. There was no significant difference in DMPK expression between DM patient biopsies and biopsies from unaffected controls.
There were no statistically significant differences in 59 or DMAHP gene expression between the DM and control groups.
Correlation of expression level with repeat number
The level of expression of each gene was plotted against the DM CTG repeat number, ascertained from the peripheral blood leukocytes by standard methodologies, for each DM patient. The results are displayed as histograms in Figure 4 and the data were used to calculate the correlation between CTG repeat length and levels of gene expression. All the data displayed in the histograms are based around a single analysis of each biopsy sample (i.e. there are no replicate datasets from an individual biopsy) and all the data were therefore used in calculating the correlation coefficients. For both DMPK and 59 levels there was a striking degree of correlation: for DMPK expression and repeat number the correlation coefficient was calculated as r = -0.7973, r 2 = 0.64, P = 0.0033. For 59 expression and repeat number the correlation coefficient was r = -0.8670, r 2 = 0.75, P = 0.0025. There is no obvious correlation between repeat number and expression levels of DMAHP and this was confirmed by statistical analysis (r = 0.2236, P = 0.7833).
DISCUSSION
The issue of the effects of the DM CTG expansion on the expression of the DM locus genes has been the subject of much debate. For technical reasons associated with the relatively low level expression of 59 and DMAHP, much of the published work has relied on the use of DM patient-derived cell lines. These are often fibroblastic in origin or their exact cellular phenotype has been poorly defined. Although the use of cell lines increases the ease with which certain assays can be performed, they have the disadvantage that they may not fully represent the situation in intact tissue. For this reason all assays in this study were performed on skeletal muscle biopsies, as the skeletal muscle is one of the tissue systems most commonly affected in DM. Our results represent the largest sample of patient biopsy material (rather than cell culture) assayed for expression of 59 or DMAHP. Due to the small size of the muscle biopsies (typically 25-50 mg) a sensitive and reproducible technique was required. The great bulk of the published work uses standard RT-PCR, which is relatively straightforward, but fails to control adequately for several important potential sources of error. Competitive RT-PCR, based on at least three dilutions of each cDNA sample and normalized to a housekeeping gene was selected for this study as it controls for variations in mRNA extraction efficiencies, reverse transcription efficiencies, intersample variation in the PCR and imprecisions in gel loading and thus represents a technical advance over the majority of the previously published studies.
The most physiologically relevant issue under the gene dosage model of DM molecular pathology is the overall expression level of each gene and thus we have used an approach which analyses total levels of cytoplasmic polyadenylated mRNA for each transcript. Our data show that, with one exception, there is a substantial overlap between the expression levels of each gene in the DM and control populations, resulting in no statistically significant differences between the groups. The exception was the significantly lower levels of DMPK in DM patient skeletal muscles, compared with those from myopathic controls. However, this actually reflects increased levels of DMPK expression in our non-DM myopathic control group and almost certainly explains the supposed decrease in DMPK levels in DM tissues reported by Fu et al. (16) . The reasons for this increase in DMPK levels in the myopathic controls are unknown, but may suggest up-regulation during certain processes in skeletal muscle. Our sample sizes are too small to analyse this in any greater depth, but it would be interesting to determine if, for example, there are different levels of DMPK expression in skeletal muscles from patients with a disease in which skeletal muscle regeneration is found, compared with those in which it does not occur. We are currently testing this hypothesis of regeneration-induced increases in DMPK expression, using a mouse model. The data for DMPK expression which we have generated using our standardized technique and intact patient material superficially contrasts with a number of previous studies. However, in many of the published reports the clearest finding has been that there is a decrease in the levels of the mature processed transcript from the expanded allele, whereas the consequences for total levels of DMPK expression are less clear cut. Hamshere et al. (17) and Davis et al. (18) both reported that the mutant DMPK transcript was retained in the nucleus, probably tightly associated with the nuclear matrix. Davis et al. (18) also claimed that the mutant transcript could only be extracted from the nucleus using caesium chloride centrifugation, which was not used in this study. We have therefore analysed predominantly cytoplasmic DMPK, if the earlier papers are correct, and shown that the levels of potentially translatable DNA in DM adult skeletal muscle samples and those from controls overlap substantially.
Also in apparent contrast to our findings for DMPK are two papers in which expression was assessed by competitive RT-PCR, both of which reported an apparent increase in DMPK transcript levels in DM patient material. However, in Sabouri et al. (21) , only one DM sample (brain tissue from a 1.5- Figure 2 . The ratio of expression of each of the DM locus genes to GAPDH was calculated for the three patient groups (log scale y-axis for clarity). (a) DMPK/GAPDH ratio: unaffected n = 13, myopathic controls n = 11, DM patients n = 11. (b) 59/GAPDH ratio: unaffected n = 12, myopathic controls n = 8, DM patients n = 9. (c) DMAHP/GAPDH ratio: unaffected n = 7, myopathic controls n = 2, DM patients n = 5. Un, unaffected controls; Myop, non-DM myopathic controls; DM, DM patients. month-old congenitally affected DM case) was tested and the normal fetal brain with which it was compared may not have been the most appropriate control. Indeed, in the other report, increased DMPK levels in skeletal muscle samples from congenitally affected infants were postulated to be the result of a delay in the development of the DM patient muscles (22) . It is perfectly possible that there are different expression patterns of the DM locus genes, depending on developmental time points, with a range of implications for pathological processes.
The expression of gene 59 also showed marked overlaps in the DM patient and control groups, which is similar to the only other reported study (performed in fibroblast cell lines) (17) . Similarly, no difference was detected in DMAHP expression levels in the DM patient samples compared with the controls. The levels of DMAHP expression in the adult skeletal muscle samples were much lower than for DMPK or 59 and in some cases were too low to be reliably detected. However, this applied as much to the control groups as to the DM patients and therefore it is unlikely that a significant type II error has been introduced into our analyses. Our findings are in agreement with those of Hamshere et al. (17) , who used fibroblast lines for the assay of gene expression, but contrast with the findings of Klesert et al. (20) and Thornton et al. (19) , both of whom claimed that DMAHP levels dropped in cell lines. Thornton et al. (19) also reported a decrease in DMAHP expression levels in patient tissues, but their numbers (two patients) were too small to perform any statistical analyses. Many of the data in the publications which reported a drop in DMAHP levels in DM patient-derived material were based on allele-specific analyses and claimed that there was a specific decrease in expression from the allele associated with the expanded CTG repeat, but were more difficult to interpret on the most physiologically significant issue of overall DMAHP transcript levels. Taken together, the generally very low level of DMAHP in adult skeletal muscle, the overlap in expression levels between the DM and control groups and the lack of any correlation of CTG expansion length with expression levels in DM tissues argue against a CTG-mediated DMAHP gene dosage model as being a likely mechanism for DM molecular pathology in this tissue. Interestingly, Murakami et al. (23) have reported that DMAHP is expressed more highly in fetal than in adult skeletal muscle and we cannot exclude the possibility that perturbations in expression levels may occur at this early time point in the presence of the CTG expansion.
However, in contrast to DMAHP, whose expression levels appear to be completely unrelated to the expansion size, there was a significant inverse correlation of DMPK expression and 59 expression with repeat length in the DM patient group. This suggests that the CTG expansion may be an important modifier of expression of these genes (accounting for up to 75% of the observed variation in expression in 59 and 64% of the variation in DMPK), although it is also possible that the observed correlation is actually due to another as yet unidentified linked factor. We have, however, excluded age as a factor influencing DM locus gene expression levels in our DM patients (for 59 r = 0.5043, P = 0.1662; for DMPK r = 0.231, P = 0.1662). As outlined above, one previously reported effect of the expansion almost certainly operates at the mRNA level, by nuclear sequestration of expansion transcripts (17, 18) . It is unlikely, however, that this same effect could be operating on 59, as the transcript from this gene does not encompass the CTG repeat. However, it has been shown in vitro that the expanded CUG repeat in the mutant DMPK transcript may affect processing of other unrelated transcripts, e.g. cardiac troponin T, and it is Figure 3 . The mean ratio of expression of each of the DM locus genes to GAPDH was calculated for the three patient groups, based on the data shown in Figure 2 . (a) DMPK/GAPDH ratio: unaffected n = 13, myopathic controls n = 11, DM patients n = 11 (see text for statistics). (b) 59/GAPDH ratio: unaffected n = 12, myopathic controls n = 8, DM patients n = 9. Myopathy versus unaffected P = 0.4179; myopathy versus DM P = 0.1388; DM versus unaffected P = 0.6958. (c) DMAHP/GAPDH ratio: unaffected n = 7, myopathic controls n = 2, DM patients n = 5. DM versus unaffected P = 0.3434; for the myopathy patients n = 2, therefore no statistical analyses were performed. Un, unaffected controls; Myop, non-DM myopathic controls; DM, DM patients. conceivable that such a mechanism may account for the findings reported here for 59 (13) .
The inverse correlation of expression of DMPK and 59 with expansion size is based on the repeat size in the peripheral blood leukocytes. This is interesting in light of the data of Zatz et al. (24) , who demonstrated a stronger correlation of symptom severity with peripheral blood expansion size than with that in the skeletal muscles, even though it is well established that the repeat is always larger in the skeletal muscles than the blood leukocytes of an individual symptomatic patient (25, 26) . Although it would be of great interest to determine whether the inverse correlation detected in our study holds true for the skeletal muscle expansion, due to the very small size and limited availability of the muscle biopsies and the technical difficulties in accurately sizing the very large repeats (for which standard Southern blotting may be inadequate), it was not possible to perform such an analysis.
In those cases where more than one piece of material was available from a single DM patient biopsy, expression levels of a particular gene were usually reasonably consistent, the exception being expression of DMAHP in samples 5A and 5B. This may be consistent with the concept that levels of DMPK and 59, but not DMAHP, are influenced by the length of the CTG expansion. However, our sample sizes are too small to indicate whether there is substantial variation in the expression levels of the genes, both within and between skeletal muscles. We are currently attempting to address this question, using mice as a model organism. It was also noticeable that the patient with the smallest expansion size had relatively high levels of both DMPK and 59, including levels of DMPK far in excess of those in any of the controls. Whether this will prove to be common to most DM patients in this minimal expansion range is the subject of further study.
Whilst our data are inconsistent with a simple gene dosage model of DM pathology, it is possible that haploinsufficiency may contribute to the phenotype in a subset of patients. There is clearly a wide range of DMPK expression amongst the control population; it is conceivable that for an individual at the lower end of expression levels, a further decrease caused by an expanded CTG repeat might be sufficient to produce pathologically significant reductions in levels of the transcript. In contrast, for an individual with a 'naturally high background' level of expression a decrease concomitant on the CTG expansion would not result in transcript levels low enough to produce significant perturbations in overall expression from the relevant gene. This may also include a degree of compensation from the normal allele, as has been suggested previously, and may be influenced by the tissue-specific expression patterns of a gene, e.g. 59 is more highly expressed in brain and testis than in skeletal muscle, and these tissues should also be examined.
In summary, we have significantly extended (and by simultaneous detection) the number of analyses of DM locus gene expression in one of the most physiologically relevant tissues in this disorder, the adult skeletal muscle, in particular for genes DMAHP and 59. Our results show that within the limits of our detection system the expansion has no detectable effect on levels of DMAHP expression, suggesting that at least in this tissue DMAHP is probably not a good candidate for involvement in molecular pathology. The levels of 59 and DMPK expression showed an inverse correlation with CTG expansion size, but are almost certainly affected by other factors as well and do not result in levels of expression different from those in the control groups. Given the Table 1 . An a or b following the number indicates two biopsies taken at the same time from a single muscle. The notation 6/1 and 6/2 refers to two biopsies taken at different times and from different muscles from the same patient (6/1 from vastus lateralis, 6/2 from tibialis anterior). As shown in Table  1 , patient 1 had the smallest CTG expansion and patient 8 the largest. Where no column is visible, this indicates either that no acceptable straight-line relationship was calculated for the competitive RT-PCR or the y = 0 point was outside the range of the line. extremely variable pattern of symptom presentation in DM, even between patients with very similar repeat sizes, it is perhaps unsurprising that our data show that a simple haploinsufficiency model of gene expression is unlikely to be the complete answer to the complex molecular pathology in this disease.
MATERIALS AND METHODS
Skeletal muscle biopsies
Percutaneous muscle biopsies were taken from either the vastus lateralis or tibialis anterior muscles, as part of standard clinical assessment. The samples were snap frozen in Freon, cooled in liquid nitrogen and stored at -80°C. Table 1 shows the clinical details of the eight DM patients from whom biopsies were available for this study. As controls, stored percutaneous muscle biopsies were used from patients with non-DM muscle disorders (Duchenne muscular dystrophy, n = 2; Becker muscular dystrophy, n = 1; tibial muscular dystrophy, n = 1; Welander's distal myopathy, n = 3; polymyositis, n = 4; all are referred to throughout as myopathic controls) and from individuals with no history of muscle disease (unaffected controls). The sample populations were age-and sex-matched as much as possible. Table 1 . Skeletal muscle biopsies from the eight DM patients were assessed and classified as mild, moderate or severe on histological examination
The relative severity of the histopathological changes is indicated by the number of + symbols accompanying each observation. The expansion size is that measured in DNA from peripheral blood leukocytes.
Patient Sex
Age at onset (years) (approximate) 
Generation of competitor clones for RT-PCR
Primer pairs were designed to generate fragments of the DMPK (exons 2-4), DMAHP (exon A) and 59 (exons 2-3) DM locus genes and the housekeeping control gene, GAPDH.
With the exception of the DMAHP gene the primers were designed to amplify cross-exonic fragments. For DMAHP there are two alternative splice isoforms of the three known exons and their relative significance is unclear; therefore, for DMAHP expression studies we analysed an intra-exonic region common to both isoforms. The same primer pairs were used in the competitive RT-PCR and were designed to yield different sized fragments easily distinguishable by PAGE. The primers and PCR product sizes are shown in Table 2 . PCRs with each primer pair were performed individually using cDNA from a control skeletal muscle biopsy sample as the DNA template and Taq DNA polymerase. The products were purified by isopropanol extraction, cloned into the pMOSBlue PCR cloning vector (Amersham International, Little Chalfont, UK) and transformed into Escherichia coli pMOS cells. Following ampicillin and blue-white selection random clones were grown in liquid culture and the plasmid DNA purified (Wizard Plus Plasmid DNA Purification kit; Promega, Southampton, UK). The inserts were sequenced to confirm their identitiy and used as templates for the inverse PCR generation of competitor clones. The inverse PCR primers shown in Table 2 were used to produce competitor clones. These primers, orientated so that their 5'-rather than 3'-ends are facing each other, are designed to bind to sequences a defined distance apart in the target fragment. Following PCR with the proof-reading enzyme Pfu polymerase which generates fragments with blunt ends, the PCR products were gel purified, religated and transformed into E.coli pMOS cells. Random clones were selected, grown in selective medium and sequenced to confirm their identity. For DMPK, DMAHP and GAPDH the expected deletions were generated; for 59 misannealing during the inverse PCR consistently generated a small duplication, which did not interfere with the competitive RT-PCR primer binding sites.
Competitive RT-PCR
Liquid cultures of the normal and competitor clones were grown and the plasmid DNA purified using the Promega Wizard Plus Preparation kit. The purity and concentration of the plasmid preparations were assessed by spectrophotometry and agarose gel electrophoresis of digested plasmid.
Poly(A) + mRNA was extracted from the skeletal muscle biopsies using the Micro Fast Track mRNA extraction kit (Invitrogen, Leek, The Netherlands). First strand cDNA was generated from 0.5 µg of the mRNA using the cDNA cycle synthesis kit (Invitrogen), and random primers. In PCR controls in which reverse transcriptase enzyme was not included during the cDNA synthesis step we did not detect genomic DNA contamination (data not shown).
Following preliminary experiments to determine the appropriate quantities of competitor DNA to use, standard volumes of the cDNA were mixed with standard amounts of the competitors. All competitor stocks were diluted and pooled together and the same diluted preparations used throughout the subsequent multiplex experiments. Either three or five dilutions of competitor DNA pools were used for each sample, depending on initial assessment of the GAPDH levels in the cDNA sample. As the levels of GAPDH were much higher than the other genes, the cDNA sample and pooled competitor stocks were mixed and then a set proportion of the mixture was removed for the assessment of GAPDH levels. PCRs were performed in 50 µl volumes, containing 10 pmol primers, 2.5 U Taq polymerase (Sigma Aldrich Chemical, Poole, UK), 10 mM Tris-HCl, pH 8.3, 5 mM KCl, 1.5 mM MgCl 2 , 0.001% gelatin (w/v) and 200 µM dNTPs in the presence of 1.5 µCi [α-32 P]dCTP (annealing temperature 59°C). Following PCR amplification, 10 µl of the PCR product were mixed with 2 µl of loading dye, boiled for 2 min and 2.5 µl of the mix electrophoresed on a 6% polyacrylamide/1× TBE 60 cm length gel for 4 h at 60 W. Band intensities were recorded using a Fuji BAS 1500 Phosphorimager.
Calculations
Following phosphorimager recording, the band intensities for the competitor products were normalized to those of the standard products, based on relative dCTP content. The log of the band ratios was calculated and graphs plotted for each sample and gene, of log competitor quantity (x-axis) against log band intensity ratio (y-axis). The amount of competitor at a value of y = 0 (band intensity equivalence) was calculated and normalized to a standard starting volume of cDNA. This value for the DM locus genes was divided by the value for the GAPDH gene.
All statistical comparisons were performed using nonparametric analyses (Mann-Whitney for intergroup comparisons and Spearman non-Gaussian analysis for correlations). 
